Acumen Pharmaceuticals (ABOS) Stifel’s 2025 Virtual CNS Forum summary

Company overview and strategy

• Focused on developing sabirnetug, a monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.

• Leveraging a team with extensive CNS and Alzheimer's drug development experience.

• Aims to offer innovative treatments that preserve quality time for Alzheimer's patients.

Clinical development progress

• Phase I INTERCEPT-AD study showed strong safety, low ARIA incidence, and clear target engagement with sabirnetug.

• Observed dose-dependent target engagement and significant biomarker changes, including reductions in amyloid PET and neurodegeneration markers.

• Phase II ALTITUDE-AD study is enrolling 540 patients, with completion of enrollment expected in the first half of 2025.

Differentiation and competitive landscape

• Sabirnetug is highly selective for toxic oligomers, distinguishing it from other agents like Leqembi and donanemab.

• Clinical adoption of first-generation A beta drugs has been slow due to infrastructure challenges, but the field is progressing.

• A beta treatments are expected to remain central to Alzheimer's therapy, with complementary mechanisms emerging over time.